Objective: To test the hypothesis that once-daily treatment with fluticasone ... receiving fluticasone propionate 50µg twice daily via a Diskus™ inhalation device. Patients whose asthma was ...

Treatment for two weeks with either oral prednisolone (30 mg/day), high dose fluticasone propionate (2000 μg/day, FP2000), or lower dose FP (500 μg/day, FP500), both given by a dry powder inhaler, ...

This was a randomised, double-blind, parallel-group study that was conducted in 86 UK primary-care centres. Patients attended the clinic on five occasions: before and after the 4-week run-in ...

After hours: December 24 at 4:52:43 PM EST ...

Teva will make two inhaler products available through this program: generic versions of the AirDuo®RespiClick® (fluticasone propionate/salmeterol xinafoate maintenance inhaler) and ProAir® HFA ...

Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), and ...

Inhalation lung delivery presents a promising alternative ... This customization capability aligns with the need for personalized treatment approaches, enhancing device versatility and clinical ...

Teva will make two inhaler products available through this program: generic versions of the AirDuo®RespiClick® (fluticasone propionate/salmeterol xinafoate maintenance inhaler) and ProAir® HFA ...

Patients had mild to moderately severe COPD (FEV 1 25–80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 μg twice daily, n=14) or placebo (n=10). Biopsy ...